Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
$0.00
$4.35
$11.97
$1.01B4.52528,025 shs1.43 million shs
Omeros Corporation stock logo
OMER
Omeros
$14.13
-3.5%
$12.00
$2.95
$17.65
$1.06B2.661.08 million shs859,553 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.14
+1.8%
$1.17
$0.98
$1.60
$845.70M1.422.32 million shs1.94 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.00%0.00%0.00%0.00%0.00%
Omeros Corporation stock logo
OMER
Omeros
-1.28%+0.27%+33.33%+30.37%+130.55%
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.00%-0.44%-4.27%-9.68%-10.04%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
$0.00
$4.35
$11.97
$1.01B4.52528,025 shs1.43 million shs
Omeros Corporation stock logo
OMER
Omeros
$14.13
-3.5%
$12.00
$2.95
$17.65
$1.06B2.661.08 million shs859,553 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.14
+1.8%
$1.17
$0.98
$1.60
$845.70M1.422.32 million shs1.94 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.00%0.00%0.00%0.00%0.00%
Omeros Corporation stock logo
OMER
Omeros
-1.28%+0.27%+33.33%+30.37%+130.55%
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.00%-0.44%-4.27%-9.68%-10.04%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.00
N/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
2.83
Moderate Buy$40.33185.44% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.17
Hold$1.5535.96% Upside

Current Analyst Ratings Breakdown

Latest OPK, OMER, and CNTTF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/4/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
DowngradeSell (D-)Sell (E+)
4/29/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
DowngradeOutperformMarket Perform
4/21/2026
Omeros Corporation stock logo
OMER
Omeros
Reiterated RatingSell (D-)
4/21/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
Reiterated RatingSell (D-)
4/21/2026
Omeros Corporation stock logo
OMER
Omeros
Reiterated RatingBuy$36.00
4/2/2026
Omeros Corporation stock logo
OMER
Omeros
UpgradeHoldStrong-Buy
3/2/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
Lower Price TargetOutperform$2.25 ➝ $1.50
(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
$15.96M0.00N/AN/AN/ANaN
Omeros Corporation stock logo
OMER
Omeros
N/AN/A$1.81 per share7.82($1.71) per shareN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
$606.90M1.42N/AN/A$1.60 per share0.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A$0.07137.18N/AN/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
-$3.35M-$0.50N/AN/AN/AN/A-72.14%59.71%5/21/2026 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$225.68M-$0.27N/AN/AN/A-36.63%-16.78%-10.98%N/A

Latest OPK, OMER, and CNTTF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2026Q1 2026
Omeros Corporation stock logo
OMER
Omeros
-$0.3007N/AN/AN/A$10.13 millionN/A
4/28/2026Q1 2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.07N/A-$0.07$130.51 million$124.20 million
3/31/2026Q4 2025
Omeros Corporation stock logo
OMER
Omeros
-$0.55$3.14+$3.69$0.98$40.15 millionN/A
2/26/2026Q4 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.04+$0.03-$0.04$139.76 million$148.50 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
N/A
2.76
2.76
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.28
3.61
3.17

Institutional Ownership

CompanyInstitutional Ownership
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.08%
Omeros Corporation stock logo
OMER
Omeros
48.79%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%

Insider Ownership

CompanyInsider Ownership
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A
Omeros Corporation stock logo
OMER
Omeros
12.90%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
CompanyEmployeesShares OutstandingFree FloatOptionable
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A105.61 millionN/ANot Optionable
Omeros Corporation stock logo
OMER
Omeros
21072.17 million62.86 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
1,373755.09 million379.89 millionOptionable

Recent News About These Companies

OPKO Health Q1 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
CannTrust stock logo

CannTrust OTCMKTS:CNTTF

CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

Omeros stock logo

Omeros NASDAQ:OMER

$14.13 -0.51 (-3.48%)
Closing price 04:00 PM Eastern
Extended Trading
$14.28 +0.15 (+1.10%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.14 +0.02 (+1.79%)
Closing price 04:00 PM Eastern
Extended Trading
$1.14 0.00 (-0.44%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.